cmAngio® vs Lung Density Analysis

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

cmAngio®

by CureMetrix

Lung Density Analysis

by 4DMedical

AI Verdict

Tool A is designed for detecting Breast Arterial Calcifications on mammograms to assess cardiovascular risk, primarily impacting women's health. In contrast, Tool B focuses on quantitative analysis of lung conditions such as COPD and emphysema using CT scans for pulmonary disease management. While both are AI-powered medical imaging solutions, their distinct anatomical targets, imaging modalities, and primary clinical applications make them suitable for different diagnostic pathways.

Choose cmAngio® if…

Choose cmAngio® if your primary objective is to integrate cardiovascular risk assessment into routine mammography screenings for women. This tool is ideal for identifying Breast Arterial Calcifications (BAC) on both FFDM and DBT exams, providing insights into cardiovascular health without requiring additional radiation or procedures.

View cmAngio® →

Choose Lung Density Analysis if…

Choose Lung Density Analysis if you require detailed quantitative analysis and 3D visualization of lung conditions from CT scans, especially for diagnosing and managing diseases like COPD and emphysema. This tool is best suited for comprehensive pulmonary assessment, offering automated workflows, noise reduction for low-dose scans, and patient-centered reports for personalized lung care.

View Lung Density Analysis →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	cmAngio®	Lung Density Analysis
Pricing	Paid, out-of-pocket	Unknown
Deployment	Cloud-based, integrates with any DICOM-compliant viewer	Unknown
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Unknown

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	cmAngio®	Lung Density Analysis
Primary Detection/Analysis Focus	Detecting Breast Arterial Calcifications (BAC) on mammograms.	Quantitative analysis and 3D visualization of lung conditions from CT scans.
Company	CureMetrix	IMBIO
Input Imaging Modality	Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams	CT scans (validated for low-dose CT scans in lung cancer screening)
Key Output/Visualization	Visualization of BAC location on a scorecard	Automated detection, visualization, and quantification of emphysema; Patient-centered LungMapu2122 report; Quantitative reports with coronal, axial, sagittal visuals and bar charts; 3D visualization.
Target Conditions/Diseases	Insights into cardiovascular health, aiding early risk assessment (related to BAC).	COPD, emphysema, Asthma, BOS, lung cancer screening.

Videos

Demos, reviews, and walkthroughs featuring cmAngio® and Lung Density Analysis.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What specific clinical conditions and anatomical regions do cmAngiou00ae and Lung Density Analysis target?

cmAngiou00ae by CureMetrix is FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health. IMBIO's Lung Density Analysis is an AI-driven software that provides quantitative analysis and 3D visualization of lung conditions like COPD and emphysema from CT scans.

Which medical imaging modalities are compatible with each AI software?

cmAngiou00ae processes both Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams. IMBIO's Lung Density Analysis is designed for quantitative analysis and 3D visualization from CT scans.

Which medical specialties are primarily served by cmAngiou00ae versus Lung Density Analysis?

cmAngiou00ae is designed for Cardiology, Obstetrics & Gynecology, and Radiology specialties. Lung Density Analysis primarily serves Pulmonology and Radiology specialties.

Does either tool offer specific features for low-dose imaging or patient counseling reports?

IMBIO's Lung Density Analysis includes Imbio Noise Reduction Technology (NRT) for low-dose scans and offers a patient-centered LungMapu2122 report for smoking cessation counseling. cmAngiou00ae does not mention specific features for low-dose imaging or patient counseling reports, but it enables BAC identification and reporting without additional radiation.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring cmAngio® or Lung Density Analysis

Backers

Who funded each tool's parent company.

cmAngio®

Keshif Ventures